Id: | acc0671 |
Group: | 1sens |
Protein: | DRP1 |
Gene Symbol: | DNM1L |
Protein Id: | O00429 |
Protein Name: | DNM1L_HUMAN |
PTM: | phosphorylation |
Site: | Ser616 |
Site Sequence: | SKPIPIMPASPQKGHAVNLLD |
Disease Category: | Cancer |
Disease: | Oral Cancer |
Disease Subtype: | SCC |
Disease Cellline: | CAL27 |
Disease Info: | |
Drug: | alantolactone |
Drug Info: | "Alantolactone is a sesquiterpene lactone derived from the roots of *Inula helenium* (elecampane), traditionally used in herbal medicine for its anti-inflammatory and antimicrobial properties." |
Effect: | modulate |
Effect Info: | "Adamantanone lactone downregulates the phosphorylation of Drp1, thereby inhibiting the proliferation and promoting the apoptosis of OSCC." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 37198593 |
Sentence Index: | 37198593_0 |
Sentence: | Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells. |
Sequence & Structure:
MEALIPVINKLQDVFNTVGADIIQLPQIVVVGTQSSGKSSVLESLVGRDLLPRGTGIVTRRPLILQLVHVSQEDKRKTTGEENGVEAEEWGKFLHTKNKLYTDFDEIRQEIENETERISGNNKGVSPEPIHLKIFSPNVVNLTLVDLPGMTKVPVGDQPKDIELQIRELILRFISNPNSIILAVTAANTDMATSEALKISREVDPDGRRTLAVITKLDLMDAGTDAMDVLMGRVIPVKLGIIGVVNRSQLDINNKKSVTDSIRDEYAFLQKKYPSLANRNGTKYLARTLNRLLMHHIRDCLPELKTRINVLAAQYQSLLNSYGEPVDDKSATLLQLITKFATEYCNTIEGTAKYIETSELCGGARICYIFHETFGRTLESVDPLGGLNTIDILTAIRNATGPRPALFVPEVSFELLVKRQIKRLEEPSLRCVELVHEEMQRIIQHCSNYSTQELLRFPKLHDAIVEVVTCLLRKRLPVTNEMVHNLVAIELAYINTKHPDFADACGLMNNNIEEQRRNRLARELPSAVSRDKSSKVPSALAPASQEPSPAASAEADGKLIQDSRRETKNVASGGGGVGDGVQEPTTGNWRGMLKTSKAEELLAEEKSKPIPIMPASPQKGHAVNLLDVPVPVARKLSAREQRDCEVIERLIKSYFLIVRKNIQDSVPKAVMHFLVNHVKDTLQSELVGQLYKSSLLDDLLTESEDMAQRRKEAADMLKALQGASQIIAEIRETHLW
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACDNM1L-Ser616 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | |
HGSC | |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
S | 616 | P | Huntington's disease | Phosphorylation | 29397067 |
S | 616 | U | Alzheimer's disease | Phosphorylation | 37174687 |
S | 616 | U | Kidney cancer | Phosphorylation | 35927303 |
S | 616 | U | Nasopharyngeal carcinoma | Phosphorylation | 32433544 |
S | 616 | U | Parkinson's disease | Phosphorylation | 31308800 |
S | 616 | U | Pulmonary hypertension | Phosphorylation | 37442283 |
S | 616 | U | Heart failure | Phosphorylation | 27739424 |
S | 616 | U | Pancreatic cancer | Phosphorylation | 25658205 |
S | 616 | U | Oral cancer | Phosphorylation | 36779631 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.